November 19, 2016

Efficacy and Safety of Sparsentan, a Dual Angiotensin II (Ang II) and Endothelin (ET) Type A Receptor Antagonist, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Phase 2 Trial (DUET)

High Impact Clinical Trials ASN 2016

Howard Trachtman, Peter J. Nelson, Radko Komers

In the phase 2 DUET trial that included 96 patients with focal segmental glomerulosclerosis (FSGS), sparsentan, a dual angiotensin II and endothelin type A receptor antagonist, was evaluated to determine the impact on proteinuria.

As compared to irbesartan, urinary protein excretion was suppressed to a greater extent than blockade of angiotensin II alone.  No hard clinical endpoints were evaluated.

Related Articles:

Clinical Trial Results, Conference Alert